126 related articles for article (PubMed ID: 30784192)
1. Cetuximab and methotrexate in recurrent or metastatic head and neck squamous cell carcinoma-A single institution analysis of 54 patients.
Sukari A; Nagasaka M; Diab M; Al Sibai K; Atassi B; Elayoubi JA; Kim S; Küçük Ö
Clin Otolaryngol; 2019 Jul; 44(4):639-643. PubMed ID: 30784192
[No Abstract] [Full Text] [Related]
2. Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy.
Magnes T; Melchardt T; Weiss L; Mittermair C; Neureiter D; Klieser E; Gampenrieder S; Moser G; Gaggl A; Greil R; Egle A
PLoS One; 2017; 12(7):e0180995. PubMed ID: 28686697
[TBL] [Abstract][Full Text] [Related]
3. The EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): treatment outcome in a single institution cohort.
Lynggaard CD; Therkildsen MH; Kristensen CA; Specht L
Acta Oncol; 2015 Jul; 54(7):1071-5. PubMed ID: 25342535
[No Abstract] [Full Text] [Related]
4. Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer.
Bossi P; Kornek G; Lanzetta G; Rozzi A; Füreder T; Locati L; Licitra L
Head Neck; 2013 Oct; 35(10):1471-4. PubMed ID: 23042567
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and toxicity of cetuximab with chemotherapy in recurrent and metastatic head and neck cancer: A prospective observational study.
Tiwari S; Goel V; John MC; Patnaik N; Doval DC
Indian J Cancer; 2016; 53(4):487-492. PubMed ID: 28485336
[TBL] [Abstract][Full Text] [Related]
6. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab-based therapy in recurrent/metastatic head and neck squamous cell carcinoma: experience from an area in which betel nut chewing is popular.
Chang PM; Hsieh YY; Chen MH; Tzeng CH; Chu PY; Chang SY; Chen PM; Yang MH
J Chin Med Assoc; 2010 Jun; 73(6):292-9. PubMed ID: 20603086
[TBL] [Abstract][Full Text] [Related]
8. Methotrexate plus or minus cetuximab as first-line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib-randomized phase II study Commence.
Ham JC; van Meerten E; Fiets WE; Beerepoot LV; Jeurissen FJF; Slingerland M; Jonker MA; Husson O; van der Graaf WTA; van Herpen CML
Head Neck; 2020 May; 42(5):828-838. PubMed ID: 31903657
[TBL] [Abstract][Full Text] [Related]
9. Modified TPEx as First-line Treatment for Recurrent and/or Metastatic Head and Neck Cancer.
Suzuki M; Takenaka Y; Kishikawa T; Yamamoto Y; Hanamoto A; Tomiyama Y; Fukusumi T; Michiba T; Takemoto N; Nakahara S; Inohara H
Anticancer Res; 2021 Apr; 41(4):2045-2051. PubMed ID: 33813412
[TBL] [Abstract][Full Text] [Related]
10. Afatinib in squamous cell carcinoma of the head and neck.
Specenier P; Vermorken J
Expert Opin Pharmacother; 2016 Jun; 17(9):1295-301. PubMed ID: 27160335
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck.
Okuno SH; Mailliard JA; Suman VJ; Edmonson JH; Creagan ET; Nair S; Levitt R; Kugler JW
Cancer; 2002 Apr; 94(8):2224-31. PubMed ID: 12001121
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Cohen EEW; Soulières D; Le Tourneau C; Dinis J; Licitra L; Ahn MJ; Soria A; Machiels JP; Mach N; Mehra R; Burtness B; Zhang P; Cheng J; Swaby RF; Harrington KJ;
Lancet; 2019 Jan; 393(10167):156-167. PubMed ID: 30509740
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.
Schöffski P; Catimel G; Planting AS; Droz JP; Verweij J; Schrijvers D; Gras L; Schrijvers A; Wanders J; Hanauske AR
Ann Oncol; 1999 Jan; 10(1):119-22. PubMed ID: 10076732
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Greenhalgh J; Bagust A; Boland A; Fleeman N; McLeod C; Dundar Y; Proudlove C; Shaw R
Health Technol Assess; 2009 Oct; 13 Suppl 3():49-54. PubMed ID: 19846029
[TBL] [Abstract][Full Text] [Related]
16. Oral metronomic chemotherapy in recurrent, metastatic and locally advanced head and neck cancers.
Patil V; Noronha V; Krishna V; Joshi A; Prabhash K
Clin Oncol (R Coll Radiol); 2013 Jun; 25(6):388. PubMed ID: 23434353
[No Abstract] [Full Text] [Related]
17. Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan.
Kiyota N; Tahara M; Kadowaki S; Fuse N; Doi T; Minami H; Ohtsu A
Jpn J Clin Oncol; 2009 Apr; 39(4):225-30. PubMed ID: 19211574
[TBL] [Abstract][Full Text] [Related]
18. Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based Therapy.
Machiels JP; Van Maanen A; Vandenbulcke JM; Filleul B; Seront E; Henry S; D'Hondt L; Lonchay C; Holbrechts S; Boegner P; Brohee D; Dequanter D; Louviaux I; Sautois B; Whenham N; Berchem G; Vanderschueren B; Fontaine C; Schmitz S; Gillain A; Schoonjans J; Rottey S
Oncologist; 2016 Dec; 21(12):1416-e17. PubMed ID: 27903924
[TBL] [Abstract][Full Text] [Related]
19. Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma.
Kushwaha VS; Gupta S; Husain N; Khan H; Negi MP; Jamal N; Ghatak A
Cancer Biol Ther; 2015; 16(2):346-51. PubMed ID: 25756517
[TBL] [Abstract][Full Text] [Related]
20. Chemo re-irradiation in recurrent head and neck cancer: a single institution experience.
Katodritis N; Charalampous H; Vomvas D
J BUON; 2012; 17(2):397. PubMed ID: 22740226
[No Abstract] [Full Text] [Related]
[Next] [New Search]